LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today reported its financial results for the third quarter and nine months ended September 30, 2008, and stated that LibiGel (testosterone gel) for the treatment of female sexual dysfunction continues as BioSante’s number one focus. LibiGel currently is in three Phase III clinical trials to support submission and approval of a new drug application (NDA) with the FDA. The LibiGel Phase III safety and efficacy trials are being conducted under an FDA approved SPA.
